Phase II Study of Ropeginterferon Alfa-2b for Patients With Dynamic International Prognostic Scoring System Low/Intermediate-1–Risk, Prefibrotic Primary MF
Ropeginterferon alfa-2b treatment of patients with low/intermediate-1–risk, prefibrotic primary myelofibrosis shows early evidence of promising efficacy and a safety profile warranting further study.